OrthoPediatrics projects $265M-$269M 2026 revenue and reiterates ~$25M adjusted EBITDA as it targets 2026 free cash flow break-even (NASDAQ:KIDS)August 5, 2026
Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10% (NASDAQ:GILD)August 5, 2026
Share Facebook Twitter LinkedIn Pinterest Email Wall Street slides as Trump threatens Apple & the European Union with tariffs
OrthoPediatrics projects $265M-$269M 2026 revenue and reiterates ~$25M adjusted EBITDA as it targets 2026 free cash flow break-even (NASDAQ:KIDS)August 5, 2026
Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10% (NASDAQ:GILD)August 5, 2026
Rio Tinto’s $3B asset sale lures private equity giants including Blackstone, KKR – report (RIO:NYSE)August 5, 2026
By Press Room
By Press Room
By Press Room
